Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sartorius Stedim Biotech Launches Sartoguard NF Prefilter Series

Published: Wednesday, December 05, 2012
Last Updated: Wednesday, December 05, 2012
Bookmark and Share
Innovative nanofleece technology provides high flow rates and total throughput performance in combination with excellent clarification capabilities.

Sartorius Stedim Biotech (SSB), a leading international pharma supplier, has launched the Sartoguard NF prefilter series, completing its range of Sartoguard prefilters. These new prefilters feature a unique combination of high performance polyethersulfone (PES) membranes and highly innovative nanofleece technology. This is the first time that PES nanofleece material is being used for liquid prefiltration applications in biopharmaceutical manufacturing. The newly developed nanofleece technology provides an ultrafine fleece structure based on a small nanofiber diameter of 120-150 nm compared with the fiber diameter of conventional fleece materials of >500 nm. The resulting fleece structure offers enhanced clarification capabilities, even for extremely fine contaminants, along with a high-dirt holding capacity, fast flow rates and high total throughput performance.

Sartoguard NF prefilters are the ideal choice for downstream protection of more expensive sterilizing-grade and Mycoplasma-retentive filters in challenging prefiltration applications for biopharmaceutical manufacturing. In combination with their high total throughput performance, Sartoguard NF prefilters offer significant cost-saving potential due to their ultrafine retention performance, which ensures removal even of extremely small particulate-based contaminants. All active filter materials – membranes and nanofleece – of the new prefilter series are made of polyethersulfone, thus ensuring a minimum extractable footprint. This enables users to easily implement Sartoguard NF into existing filtration processes utilizing final filters already based on PES.

Sartoguard NF filter elements are available in all common filter formats offered by Sartorius Stedim Biotech, such as SartoScale devices for small-scale filterability trials, as well as MidiCaps, MaxiCaps and standard filter cartridges for medium- and commercial-scale manufacturing. Sartoguard NF MidiCaps and MaxiCaps are the first fully gamma irradiatable prefilter series and can be easily integrated into single-use process equipment.

Sartoguard NF filters conclude the launch of the Sartoguard prefilter family, which includes the Sartoguard PES and Sartoguard GF prefilter series that have been successfully introduced to the market earlier. The launch of the Sartoguard prefilter family is an important contribution by Sartorius Stedim Biotech in reducing overall filtration costs in biopharmaceutical manufacturing and in helping biomanufacturers cope with the increasing cost pressure while maintaining and improving their high quality standards.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sartorius Acquires Cellca
Sartorius Stedim Biotech (SSB) acquired Cellca, a Laupheim, Germany-based company that specializes in cell line and process development.
Friday, July 03, 2015
TAP Biosystems and Merck & Co., Inc. Double Triumph at BPI 2014 Awards
“Best Collaboration” and “Best Technology Application — Upstream” Awards acknowledges ambr250 mini bioreactor system as an exceptional technology.
Monday, October 27, 2014
Sartorius Appoints Internationally Experienced Laboratory Manager
Michael Melingo to succeed Dominique Baly in the Sartorius lab business.
Friday, January 31, 2014
Sartorius Officially Opens Production Facility for Bioreactors in Guxhagen, Germany
18 million euros invested in the expansion of manufacturing capacity.
Saturday, September 15, 2012
Sartorius Officially Opens New Filter and Aseptic Bag Production Facility in Puerto Rico
Sixteen million euros invested in the expansion of production capacity.
Wednesday, June 27, 2012
Scientific News
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Study Shows Sandoz Biosimilar Equivalent to Originator Drug
New data shows Sandoz biosimilar candidate has equivalent efficacy to originator etanercept following comparison in psoriasis.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Immunotherapy Reduces Rheumatoid-Linked Cardiovascular Risk
Study shows combination of two extra-low dose anticytokines reduces disease activity and cardiovascular events.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
Sanofi Working on Zika Vaccine with U.S. Army
Sanofi is working in conjunction with the U.S. Army to develop possible Zika vaccine at faster rate following research agreement.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!